Condition
Malignant Pleural Mesothelioma
Estimated Enrollment: 20
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: CCRG13-002
Study First Received: December 7, 2015
Last Updated: January 24, 2017
Estimated Primary Completion Date: October 2020
Primary Outcome Measures:
Number of MPM patients with feasible and safe DC vaccine production|Number of patients receiving investigational DC vaccine administration combined with standard of care chemotherapy within the proposed time frame|Objective clinical responses by tumor evaluation (clinical efficacy)|Overall survival (clinical efficacy)|Systemic immunogenicity|Local immunogenicity
Sponsors and Collaborators:
University Hospital, Antwerp
Website Link: https://ClinicalTrials.gov/show/NCT02649829
